Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Support for Seqster
March 2020
SHARING OPTIONS:

SAN DIEGO—Seqster announced last month that it had received an investment from Takeda Pharmaceuticals of an undisclosed amount, and the company will apply the funds toward accelerating the adoption of its interoperability technology for enhancing clinical trials, patient engagement and outcomes. Seqster offers a software-as-a-service technology platform that enables person-centric health data management. The company recently released Seqster Version 5.0 to offer better patient outcomes, generate actionable data and enhance value.
 
“Our funding of Seqster is a cornerstone of our digital health strategy, and further enables us to serve our patient community by advancing the deployment of innovative technology solutions,” stated Bruce Meadows, head of Investments at Takeda Digital Ventures. “Seqster’s technology is a very unique platform that addresses interoperability on not only a nationwide scale but also globally. Interoperability is one of the biggest barriers to applying precision medicine to clinical trials and patient engagement.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.